End of the line looms for Aradigm as it files for bankruptcy by Phil Taylor Tuesday, February 19, 2019 Aradigm’s bid to get an inhaled antibiotic to market seems at an end, with its assets up for sale and the jobs of two primary executives terminated.
Aradigm executives jump ship after FDA snub by Amirah Al Idrus Wednesday, February 14, 2018 Aradigm's CEO, chief medical officer and chief financial officer resigned.
FDA demands 2-year phase 3 from Aradigm by Nick Paul Taylor Monday, January 29, 2018 The FDA recommendation leaves Aradigm potentially needing to raise a sizable sum of money at a time when its stock is plumbing new depths.
Aradigm crashes after FDA panel votes down antibiotic by Nick Paul Taylor Friday, January 12, 2018 The panel felt Aradigm failed to show evidence of the safety and efficacy of Linhaliq in delaying the first exacerbation in chronic lung infections.
